TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
Fiscal Year Ended December 31, 2023
For Fiscal Year Ending December 31, 2023
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.
TC BioPharm (TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.
TC BioPharm Limited
Maxim 1
2 Parklands Way
Holytown, Motherwell ML1 4WR
United Kingdom
T: +44 (0) 141 433 7557
info@tcbiopharm.com
Computershare Investor Services PLC